JP2022548866A5 - - Google Patents

Info

Publication number
JP2022548866A5
JP2022548866A5 JP2022516320A JP2022516320A JP2022548866A5 JP 2022548866 A5 JP2022548866 A5 JP 2022548866A5 JP 2022516320 A JP2022516320 A JP 2022516320A JP 2022516320 A JP2022516320 A JP 2022516320A JP 2022548866 A5 JP2022548866 A5 JP 2022548866A5
Authority
JP
Japan
Prior art keywords
item
nucleic acid
recombinant nucleic
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548866A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050503 external-priority patent/WO2021050948A1/en
Publication of JP2022548866A publication Critical patent/JP2022548866A/ja
Publication of JP2022548866A5 publication Critical patent/JP2022548866A5/ja
Pending legal-status Critical Current

Links

JP2022516320A 2019-09-12 2020-09-11 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法 Pending JP2022548866A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899563P 2019-09-12 2019-09-12
US62/899,563 2019-09-12
US202062971682P 2020-02-07 2020-02-07
US62/971,682 2020-02-07
PCT/US2020/050503 WO2021050948A1 (en) 2019-09-12 2020-09-11 Compositions and methods for tcr reprogramming using fusion proteins

Publications (2)

Publication Number Publication Date
JP2022548866A JP2022548866A (ja) 2022-11-22
JP2022548866A5 true JP2022548866A5 (enExample) 2023-09-20

Family

ID=74866684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516320A Pending JP2022548866A (ja) 2019-09-12 2020-09-11 融合タンパク質を用いたｔｃｒリプログラミングのための組成物及び方法

Country Status (10)

Country Link
EP (1) EP4028033A4 (enExample)
JP (1) JP2022548866A (enExample)
KR (1) KR20220078607A (enExample)
CN (1) CN114828862A (enExample)
AU (1) AU2020344628A1 (enExample)
BR (1) BR112022004458A2 (enExample)
CA (1) CA3154287A1 (enExample)
IL (1) IL291236A (enExample)
MX (1) MX2022002984A (enExample)
WO (1) WO2021050948A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
EP4217377A4 (en) * 2020-09-23 2024-11-27 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells
WO2023091420A2 (en) * 2021-11-16 2023-05-25 TCR2 Therapeutics Inc. Compositions and methods for t cell engineering
US20260007747A1 (en) * 2022-01-07 2026-01-08 Vivasor, Inc. Engineered PD-L1-Targeting Gamma Delta T Cell Receptors
EP4573114A4 (en) * 2022-08-19 2026-07-29 Memorial Sloan Kettering Cancer Center T-LYMPHOCYTE RECEPTORS TARGETTING RAS MUTATIONS AND ASSOCIATED USES
WO2025217063A1 (en) * 2024-04-08 2025-10-16 Baylor College Of Medicine Dual stimulatory receptors for immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
RS61455B1 (sr) * 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
MX2018004721A (es) * 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
BR112019007100A2 (pt) * 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh) * 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CA3047999A1 (en) * 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018232020A1 (en) * 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11738047B2 (en) * 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
WO2019133443A1 (en) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Modified t cell receptors
CA3093449A1 (en) * 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins

Similar Documents

Publication Publication Date Title
JP7179041B2 (ja) 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用
JP7574243B2 (ja) 抗ｃｄ７０キメラ抗原受容体
JP2021515598A5 (enExample)
JP2022531222A5 (enExample)
KR102842215B1 (ko) Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
CN112689642B (zh) 具有各种不同的构建物优化的t细胞抗原偶联物
TW201930589A (zh) 表現特異性辨識人類間皮素之細胞表面分子、il-7、及ccl19之免疫活性細胞
JP2022501074A (ja) 血液腫瘍を治療するための遺伝子操作しているγδ−Ｔ細胞及び遺伝子操作していないγδ−Ｔ細胞に関する組成物及び方法
WO2023133357A2 (en) Engineered t cells
JP2024501831A5 (enExample)
Renner et al. RP1, a new member of the adenomatous polyposis coli-binding EB1-like gene family, is differentially expressed in activated T cells
WO2022150379A1 (en) Nk cell engager molecules and methods of use
KR102764613B1 (ko) NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물
Sasu et al. T cell redirecting therapies for cancer treatment
JP2026501830A (ja) 遺伝子操作ｔ細胞
JP2025539364A (ja) 遺伝子操作ｔ細胞
CN116209749A (zh) 靶向mage-a4肽的细胞/基因疗法
HK1234091B (en) Trifunctional t cell-antigen coupler and methods and uses thereof